Clinical Trial Update: TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing. [Phase 1]

View source ↗

Summary

Phase I study evaluating drug-drug interaction between TMC435350 and rifampin after multiple dosing in Hepatitis C patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• RIFAMPIN (RIFAMPIN)
• TMC435350

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C, HCV | Phase 1 | Status: COMPLETED